Gene · 3127
HLA-DRB5: major histocompatibility complex, class II, DR beta 5
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. HLA-DRB5: major histocompatibility complex, class II, DR beta 5. Genes, record 3127. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/3127
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q30154 | HLA class II histocompatibility antigen, DR beta 5 chain | 266 | 4 | Ensembl, GeneID, HGNC |
Source UniProt
Patents46
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 52449 | Q30154 | Espacenet |
| EP 4640849 A2 | 2025-10-29 | 1436 | Q30154 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 9809 | Q30154 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 1971 | Q30154 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 1971 | Q30154 | Espacenet |
| JP 2025519096 A | 2025-06-24 | 1436 | Q30154 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 9809 | Q30154 | Espacenet |
| JP 2025062601 A | 2025-04-14 | 12 | Q30154 | Espacenet |
| US 12029782 B2 | 2024-07-09 | 144 | Q30154 | Espacenet |
| JP 2024063050 A | 2024-05-10 | 293 | Q30154 | Espacenet |
1 to 10 of 46
See all 46 patentsDrugs1
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action |
|---|---|---|---|
| APOLIZUMAB | CHEMBL2108252 | Human leukocyte antigen DR beta chain inhibitor | INHIBITOR |
Source ChEMBL
Trials6
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT00089154 | APOLIZUMAB | PHASE2 | ClinicalTrials.gov | |
| NCT00055783 | APOLIZUMAB | PHASE2 | ClinicalTrials.gov | |
| NCT00022971 | APOLIZUMAB | PHASE1 | ClinicalTrials.gov | |
| NCT00017472 | APOLIZUMAB | PHASE1 | ClinicalTrials.gov | |
| NCT00014664 | APOLIZUMAB | PHASE2 | ClinicalTrials.gov | |
| NCT00004101 | APOLIZUMAB | PHASE1 | ClinicalTrials.gov |
NIH grants1,950
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | HLA-DRB5 papers | Newest fiscal year |
|---|---|---|---|
| U24AG021886 | National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD) | 23 | 2025 |
| P01AG019724 | Frontotemporal Dementia: Genes, Images, and Emotions | 9 | 2025 |
| P30DK063491 | Diabetes Research Center (DRC) | 8 | 2025 |
| P30CA015704 | Cancer Center Support Grant | 6 | 2025 |
| R01AI128775 | Integrated Exchange and Storage of Current- and Future-Generation Immunogenomic Data | 6 | 2025 |
| U24AG041689 | THE NIA GENETICS OF ALZHEIMER'S DISEASE DATA STORAGE SITE | 6 | 2025 |
| P30DK043351 | Center for the Study of Inflammatory Bowel Disease at Massachusetts General Hospital | 5 | 2025 |
| U01CA167551 | Colon Cancer Family Registry Cohort | 5 | 2025 |
| U01DK062432 | Montreal-Boston Collaborative GRC | 5 | 2025 |
| P01AG026276 | Antecedent Biomarkers for Alzheimer Disease: The Adult Children Study | 4 | 2025 |
1 to 10 of 1,950Source NIH's project files
See all 1,950 nih grantsPapers1,962
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Pan-cancer single-cell atlas of immunotherapy response identifies ZNF385A as a regulator of immune evasion in small cell lung cancer. | Biochim Biophys Acta Mol Basis Dis | 2027 | 42667989 | PubTator, text mining | PubMed |
| Linking HLA class II susceptibility to HSPC transcriptomics and antigen presentation in aplastic anemia. | Front Immunol | 2026 | 42774213 | PubTator, text mining | PubMed |
| Phase 1 study of KHK2455, a long-acting, potent and selective IDO1 inhibitor, in combination with avelumab in patients with locally advanced or metastatic urothelial carcinoma. | J Immunother Cancer | 2026 | 42767768 | PubTator, text mining | PubMed |
| Identification of a New HLA-DRB5 Allele in a Chinese Han Individual, HLA-DRB5*01:01:17. | HLA | 2026 | 42757947 | PubTator, text mining | PubMed |
| Rare Variants May Influence Disease Risk and Clinical Features in Sporadic Late-Onset Chinese Parkinson's Disease Patients. | Int J Mol Sci | 2026 | 42737551 | PubTator, text mining | PubMed |
| Independent prognostic value of semaphorin-4D, interleukin-1β and complement activation in newly diagnosed multiple myeloma patients. | Haematologica | 2026 | 42687818 | PubTator, text mining | PubMed |
| Interplay between monocyte subsets and leukemic blasts shapes the immune microenvironment and sustains minimal residual disease in pediatric B-cell acute lymphoblastic leukemia. | Front Immunol | 2026 | 42682678 | PubTator, text mining | PubMed |
Validation of Sequence-Specific Oligonucleotide Probe-Based HLA Homozygosity Classification Using 11-Locus Next-Generation Sequencing in Korean Cord Blood Units: Extended Haplotype Architecture and Implications for Induced Pluripotent Stem Cell Haplobanking. | Ann Lab Med | 2026 | 42661591 | PubTator, text mining | PubMed |
| Genetic subtypes of multiple sclerosis severity are uncoupled from inflammatory lesion burden. | Acta Neuropathol | 2026 | 42627512 | PubTator, text mining | PubMed |
| Sex-stratified blood transcriptomic candidate biomarkers of multiple sclerosis identified by ensemble feature selection. | Mult Scler Relat Disord | 2026 | 42607545 | PubTator, text mining | PubMed |
1 to 10 of 1,962
See all 1,962 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/3127
GET https://conductscience.org/api/genes/v1/3127/patents?page=2